Atrial fibrillation is associated with an increased risk for mortality and heart failure progression in patients with asymptomatic and symptomatic left ventricular systolic dysfunction: A retrospective analysis of the SOLVD trials

Journal of the American College of Cardiology

Volumn 32, Issue 3, 1998, Pages 695-703

  Dries, Daniel L ^a,b   Exner, Derek V ^b   Gersh, Bernard J ^b   Domanski, Michael J ^a   Waclawiw, Myron A ^a   Stevenson, Lynne W ^c  

^a NATIONAL HEART LUNG AND BLOOD INSTITUTE   (United States)

^b GEORGETOWN UNIVERSITY HOSPITAL   (United States)

^c BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIARRHYTHMIC AGENT; ANTICOAGULANT AGENT; ANTITHROMBOCYTIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; DIGOXIN; DIURETIC AGENT; ENALAPRIL;

ADULT; ARTICLE; CAUSE OF DEATH; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE CLASSIFICATION; DISEASE COURSE; FEMALE; HEART ARRHYTHMIA; HEART ATRIUM FIBRILLATION; HEART EJECTION FRACTION; HEART LEFT VENTRICLE FAILURE; HEART RATE; HOSPITALIZATION; HUMAN; MAJOR CLINICAL STUDY; MALE; MORTALITY; PRIORITY JOURNAL; PROGNOSIS; RISK FACTOR; SURVIVAL RATE;

ADULT; AGED; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ATRIAL FIBRILLATION; CAUSE OF DEATH; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; ENALAPRIL; FEMALE; HEART FAILURE, CONGESTIVE; HEMODYNAMIC PROCESSES; HUMANS; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; RISK; SURVIVAL RATE; SYSTOLE; VENTRICULAR DYSFUNCTION, LEFT;

EID: 0031686381     PISSN: 07351097     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0735-1097(98)00297-6     Document Type: Article

References (30)

1. Carson P.E., Johnson G.R., Dunkman W.B., Fletcher R.D., Farrel L., Cohn J.N. The influence of atrial fibrillation on prognosis in mild to moderate heart failure The V-HeFT Studies . Circulation. (Suppl VI:VI):1993;102-110.
2. Middlekauff H.R., Stevenson W.G., Stevenson L.W. Prognostic significance of atrial fibrillation in advanced heart failure A study of 390 patients . Circulation. 84:1991;40-48.
3. Singh S.N., Fletcher R.D., Fisher S.G., et al. Amiodarone in patients with congestive heart failure and asymptomatic ventricular arrhythmia. N Engl J Med. 333:1995;77-82.
4. Benjamin E.J., Levy D., Vaziri S.M., D'Agostino R.B., Belanger A.J., Wolf P.A. Independent risk factors for atrial fibrillation in a population-based cohort. JAMA. 271:1994;840-844.
5. Doval HC, Nul DR, Grancelli HO, Perrone SV, Bortman GR, for Grupo de Etudio La Obrevida en La Insuficienca Cardiaca En Argentina (GESICA). Randomised trial of low-dose amiodarone in severe congestive heart failure. Lancet 1994;344:493-8.
6. Clark D.M., Plumb V.J., Epstein A.E., Kay G.N. Hemodynamic effects of irregular sequence of ventricular cycle lengths during atrial fibrillation. J Am Coll Cardiol. 30:1997;1039-1045.
7. Keogh A.M., Baron D.W., Hickie J.B. Prognostic guides in patients with idiopathic or ischemic dilated cardiomyopathy assessed for transplantation. Am J Cardiol. 65:1990;903-908.
8. Hofmann T., Meinertz T., Kasper W., et al. Mode of death in idiopathic dilated cardiomyopathy a multivariate analysis of prognostic determinants . Am Heart J. 116:1988;1455-1463.
9. Fuster V., Gersh B.J., Giuliani E.R., Tajik A., Brandenberg R.O., Frye R. The natural history of idiopathic dilated cardiomyopathy. Am J Cardiol. 47:1981;525-531.
10. Juilliere Y., Danchin N., Briancon S., et al. Dilated cardiomyopathy long-term follow-up and predictors of survival . Int J Cardiol. 21:1988;269-277.
11. Stevenson W.G., Stevenson L.W., Middlekauff H.R., et al. Improving survival for patients with atrial fibrillation and advanced heart failure. J Am Coll Cardiol. 28:1996;1458-1463.
12. Studies of left ventricular dysfunction (SOLVD)-rationale, design and methods two trials that evaluate the effect of enalapril in patients with reduced ejection fraction . Am J Cardiol. 66:1990;315-322.
13. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N Engl J Med. 325:1991;293-302.
14. Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions. N Engl J Med. 327:1992;685-691.
15. Grogan M., Smith H.C., Gersh B.J., Wood D.W. Left ventricular dysfunction due to atrial fibrillation in patients initially believed to have idiopathic dilated cardiomyopathy. Am J Cardiol. 69:1992;1570-1575.
16. Heinz G., Siostrzonek P., Kreiner G., et al. Improvement in left ventricular systolic function after successful radiofrequency His bundle ablation for drug refractory, chronic atrial fibrillation and recurrent atrial flutter. Am J Cardiol. 69:1992;489.
17. Shinbane J.S., Wood M.A., Jensen D.N., Ellenbogen K.A., Fitzpatrick K.A., Scheinman M.M. Tachycardia-induced cardiomyopathy a review of animal models and clinical studies . J Am Coll Cardiol. 29:1997;709-715.
18. Naito M., David D., Michelson E.L., Schaffenberg M., Dreifus L.S. The hemodynamic consequences of cardiac arrhythmias evaluation of the relative roles of abnormal atrioventricular sequencing, irregularity of ventricular rhythm and atrial fibrillation in a canine model . Am Heart J. 106:1983;284-291.
19. Samet P., Bernstein W., Levine S. Significance of the atrial contribution to ventricular filling. Am J Cardiol. 15:1965;195-202.
20. Skinner N.S., Mitchell J.H., Wallace A.G., Sarnoff S.J. Hemodynamic consequences of atrial fibrillation at constant ventricular rates. Am J Med. 36:1964;342-350.
21. Herbert W.H. Cardiac output and the varying R-R interval of atrial fibrillation. J Electrocardiol. 6:1973;131-135.
22. Psaty B.M., Heckbert S.R., Koepsell T.D., et al. The risk of myocardial infarction associated with antihypertensive drug therapies. JAMA. 274:1995;620-625.
23. The effect of diltiazem on mortality and reinfarction after myocardial infarction. N Engl J Med. 319:1988;385-392.
24. Dries D.L., Rosenberg Y.D., Waclawiw M.A., Domanski M.J. Ejection fraction and the risk of thromboembolic events in patients with systolic dysfunction and sinus rhythm evidence for gender differences in the SOLVD trials . J Am Coll Cardiol. 29:1997;1074-1080.
25. Ziesche S., Rector T.S., Cohn J.N. Interobserver discordance in the classification of mechanisms of death in studies of heart failure. J Card Fail. 1:1995;127-132.
26. Wallis J.W., Juni J.E., Wu L. Gated cardiac blood pool studies in atrial fibrillation role of cycle-length windowing . Eur J Nucl Med. 18:1991;23-27.
27. Packer M, Bristow MR, Cohn JC, et al. for the U.S. Carvedilol Heart Failure Study Group. The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. N Engl J Med 1996;334:1349-55.
28. Singh SN, Fletcher RD, Fisher SG, et al. for the Survival Trial of Antiarrhythmic Therapy in Congestive Heart Failure. Amiodarone in patients with congestive heart failure and asymptomatic ventricular arrhythmia. N Engl J Med 1995;333:77-82.
29. Edner M., Caidahl K., Bergfeldt L., Darpo B., Edvardsson N., Rosenqvist M. Prospective study of left ventricular function after radiofrequency ablation of atrioventricular junction in patients with atrial fibrillation. Br Heart J. 74:1995;261-267.
30. Atrial fibrillation follow-up investigation of rhythm management - the AFFIRM study design. Am J Cardiol. 79:1997;1198-1202.